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High-Affinity Sequence-Selective DNA binding by 
Iridium(III) polypyridyl organometallopeptides  
Ilaria Gamba,a Iria Salvadó,a Rosa F. Brissos,b Patrick Gamez,b,c José Brea,c María 
Isabel Loza,d M. Eugenio Vázqueze,* and Miguel Vázquez Lópeza,*  
 
We demonstrate the application of solid-phase peptide 
synthesis methods for the straightforward assembly of 
polynuclear Ir(III) organometallopeptides, and show that 
their oligoarginine derivatives exhibit high DNA binding 
affinity, sequence selectivity, and high cytotoxicicty towards a 
set of cancer cell lines. 
DNA-binding drugs are the workhorse of current anticancer 
therapies.1 However, despite their extensive use, many of them 
suffer from severe side-effects, which has fuelled the search of 
safer alternatives with improved pharmacological profiles.2 In 
the past few years, there has been an increased interest in the 
application of coordination compounds as DNA-targeted 
probes, reactive agents and therapeutics,3,4,5 Among them, 
Ru(II), Os(II) and Rh(III) polypyridyl mononuclear complexes 
have been exhaustively studied for their kinetic stability and 
convenient redox and optical properties.6,7 In contrast, the 
potential of classical Werner and organometallic Ir(III) 
analogues as DNA-binding agents is still largely unexplored, 
despite being also kinetically inert and displaying excellent 
photochemical properties with tuneable excited states and long 
emission wavelengths for sensing and imaging.6e,8 Indeed, 
current examples in the literature are practically limited to 
mononuclear intercalators,9 with very few reports of di/poly-
nuclear derivatives,10,11 or groove-binding agents.9  
 We have recently reported the extension of standard solid-
phase peptide synthesis procedures (SPPS) for the construction 
of polypyridyl dinuclear Ru(II) complexes.5a Intrigued by the 
potential of Ir(III) complexes as DNA binders, we decided to 
expand the scope of this methodology to the synthesis of Ir(III) 
organometallopeptides. Considering that the DNA binding 
properties of these complexes would be highly influenced by 
their nuclearity,12 we also synthesized dinuclear and trinuclear 
derivatives in addition to the mononuclear complexes.13 Finally, 
it is also worth noting that there are very few precedents of 
Ir(III)-peptide conjugates, and limited to examples in which the 
Ir(III) complexes are attached to the N-terminus,14 or the side 
chains of the peptide chain, but never integrated in the peptide 
backbone structure. 
 Thus, based on our earlier studies with Ru(II) 
metallopeptides, we designed three peptidic ligands containing 
one, two or three βAla-bpy coordinating units (1, Scheme 1) to 
generate mono, di and trinuclear Ir(III) polypyridyl organo-
metallopeptides. The peptidic ligands were synthesized 
following standard Fmoc/tBu solid-phase protocols.15 Once 
fully assembled, the peptides still attached to the solid support 
were reacted with [Ir(ppy)2Cl]2 (ppy: 2-phenylpyridine) to give 
the desired cyclometalated complexes Ir, Ir2 and Ir3 (Scheme 
1). Acidic cleavage from the support, followed by reverse-
phase HPLC purification, afforded the desired Ir(III) 
organometallopeptides as diasteromeric mixtures. 
 
 
Scheme 1. Solid-phase peptide synthesis of the organometallopeptides Ir, Ir2 
and Ir3 
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Having at hand the desired Ir(III) organometallopeptides, we 
studied their DNA binding by exploiting the intrinsic 
environment-sensitive luminescence of the Ir(III) complexes. In 
contrast with the good DNA binding affinity of their Ru(II) 
analogs,13 the fluorescence titrations experiments carried out 
with the Ir, Ir2 and Ir3 organometallopeptides did not show any 
significant affinity for short DNA oligonucleotides, so that 
addition of increasing amounts of hairpin oligonucleotides 
containing A/T or G/C-rich sequences did not induce any 
change in the emissive properties of the organometallopeptides 
(see ESI†).  
 A possible explanation for the low DNA affinity displayed 
by these Ir(III) metallopeptides is the reduced charge of 
[Ir(ppy)2bpy]+ units (+1 charge in each complex) in comparison 
to that of the [Ru(bpy)3]+2 DNA complexes (+2). We envisaged 
that the reduced electrostatic attraction for the negatively 
charged DNA might be compensated by introducing additional 
positively charged groups, and thus we decided to synthesize 
the octaarginine derivatives of Ir, Ir2 and Ir3 (named Ir-R8, 
Ir2-R8 and Ir3-R8, respectively). Indeed, it has been shown that 
tethering octaarginine domains to DNA binding agents results 
in conjugates that display increased DNA affinity,16,17 as well 
as improved cell internalization and solubility.18,19 We took 
advantage of the flexibility provided by the SPPS methodology 
to synthesize these oligocationic metallopeptides as described 
before, assembling the βAla-bpy coordinating units at the N-
terminus of a previously synthesized R8 peptide. 
 Once we synthesized the desired oligoarginine conjugates, 
we studied their DNA binding by fluorescence spectroscopy. 
Thus, incubation of 0.2 µM solutions of Ir-R8, Ir2-R8 and  
Ir3-R8 with increasing concentrations of DNA hairpins resulted 
in a progressive increase of the 620 nm emission upon 
excitation at 320 nm (Fig 1, left). The corresponding titration 
profiles for each metallopeptide with different oligonucleotides 
could be fitted to the Bard model (Fig 1, right),20 which allowed 
us to determine the affinity constants (Ka) for the different 
DNA sequences (Table 1). These results show that the binding 
affinity is dramatically increased with respect to the parent 
metallopeptides (Ir, Ir2 and Ir3), and heavily dependent on the 
nuclearity of the metallopeptides. In fact, the Ka values are 
approximately in the order of 106, 107 and 108 M–1 for Ir-R8, 
Ir2-R8 and Ir3-R8, respectively. Besides, Ir-R8 shows a slight 
preference for for A/T-rich sequences, whereas Ir2-R8 and Ir3-
R8 display a clear preference for hairpins with high G/C 
content, perhaps suggesting alternate binding preferences for 
the two metallopeptides. 
 Interestingly, the calculated association constants for the 
interaction of Ir3-R8 for the DNA hairpin are 100 times higher 
than those typically reported for common mononuclear 
intercalating complexes (such as Ru(II)/dppz derivatives),6c and 
1000 times stronger than those observed for other non-
intercalating DNA-binding metal complexes,5a and in the order 
of the binding constants measured for widely used organic 
DNA minor-groove binders, like Hoechst 33258.17b,21 
Therefore, to the best of our knowledge, Ir3-R8 displays the 
highest DNA affinity observed for a metal complex. In order to 
explore the role of the Arg8 appendage we synthesized a 
scrambled trinuclear Ir(III) organometallopeptide in which the 
iridium centers are separated by groups of three arginine 
residues Ir-R3-Ir-R3-Ir-R3. Interestingly, this analog displayed 
negligible affinity for duplex DNA (see figures S4 and S5 in 
the ESI†), thus suggesting an important role for the C-terminal 
R8 domain beyond simple electrostatic stabilization of the 
complexes with the DNA.  
 
Table 1. DNA association constants (Ka / 106 M-1).a 
 AAAATT AAGCTT GAAGGC GGCCC 
Ir-R8 4.0 ± 0.3 3.9 ± 0.2 3.2 ± 0.2 2.7 ± 0.1 
Ir2-R8 10.7 ± 0.8 10.4 ± 0.6 13.3 ± 0.7 18.3 ± 1.4 
Ir3-R8 89.7 ± 9.2 76.8 ± 6.2 94.1 ± 9.2 158.0 ± 17.9 
a Full sequences of the hairpin oligonucleotides used in this study (binding sites 
underlined, central T4 hairpin loop in italics): AAAATT: 5’-GGC AAAATTT CG 
TTTTT CG AAATTTT GCC–3’; AAGCTT: 5’–GGC AAGCTT CGC TTTTT GCG 
AAGCTT GCC–3’; GAAGGC: 5’–GGC GAAGGC AGC TTTTT GCT GCCTTC 
GCC-3’; GGCCC: 5’–GGCA GGCCC AGC TTTTT GCT GGGCCT GCC–3’. 
Titrations were performed adding increasing amounts of the corresponding 
hairpin oligos over 0.2 µM solutions of the peptides in 100 mM phosphate buffer, 
100 mM NaCl, pH 6.8 at 25 ºC (see the ESI†). 
 
 
Fig 1. Left, Luminescence spectra of 0.2 µM solutions of Ir2-R8 in phosphate 
buffer (100 mM), NaCl (100 mM), pH 6.8 (red line) and evolution upon addition 
of aliquots of a GGCCC hairpin oligonucleotide solution (10 µM)  (black lines) 
until saturation (thick black line); right, titration profiles of Ir-R8 (black), Ir2-R8 
(red) and Ir3-R8 (blue) with GGCCC oligonucleotides. 
 The interaction of Ir2 and Ir2-R8 with DNA was 
investigated further using atomic-force microscopy (AFM). 
These studies were carried out with the relaxed pBR322 
plasmid, which allows a direct observation of all possible 
interactions with the cyclometalated complexes.22 The relaxed 
DNA molecules dispersed over a mica surface show some 
circular structures with a number of crossing points that are 
indicative of supercoiling initiation (Fig 2a, and Fig S1 in the 
ESI). Actually, some small supercoiled DNA fragments are 
observed (Fig S1 in the ESI). Incubation of Ir2 with the relaxed 
plasmid for 24 h affected the morphology of the DNA structure, 
so that significantly more crossing points are noticed, and 
longer supercoiled fragments are clearly formed  (Figs 2b, and 
S2 in the ESI). In addition, several DNA molecules start to 
aggregate, which suggest strong interactions of Ir2 with the 
biomolecule. In agreement with the fluorescence titrations, 
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incubation of pBR322 with Ir2-R8 revealed even higher affinity 
for the DNA, with the induction of a major proportion of 
supercoiled DNA and of increased aggregation; the supercoiled 
fragments are significantly longer than those observed with Ir2, 
and large open forms, such as those observed in Fig 2a, are not 
present anymore Furthermore, large complex-induced DNA 
aggregates are detected (see Fig 2c and Fig S3). Thus, the AFM 
results confirm the spectroscopic observations, and support the 
strong DNA-binding properties of Ir2-R8. Interestingly, this 
important effect of Ir2-R8 on the degree of DNA coiling 
aggregation may be compared to proteins that pack the DNA 
into chromosomes.  
 
Figure 2. AFM images of (a) free relaxed pBR322 DNA (10 µM in base pairs) 
and plasmid incubated at 37 ºC for 24 h in HEPES with (b) complex Ir2 (25 µM) 
or (c) complex Ir2-R8 (25 µM). 
Following the in vitro characterization, we evaluated the 
cytotoxicity of Ir2 and Ir2-R8 with a set of tumor cell lines 
including NCI-H460 (lung carcinoma), MCF-7 (breast cancer) 
and A2780 cis (ovarian carcinoma) cells using MTT method 
(detailed methods are reported in the ESI). In agreement with 
the DNA binding data, Ir2-R8 displayed higher cytotoxic 
activity than Ir2. Thus, Ir2 has negligible cytotoxic effects, but 
Ir2-R8 exhibits significant effects on cell viability, so that the 
observed IC50 values are comparable to those obtained for 
cisplatin under the same experimental conditions (Table 2).23 
Furthermore, the cytotoxicity of the entire set of Ir(III) R8-
organometallopeptides was examined with the model 
doxorubicin-resistance NCI/ADR-RES ovarian cell line, which 
is particularly useful for the identification of compounds 
subjected to drug resistance. Interestingly, any of the three 
Ir(III) R8-organometallopeptides caused up to 90 % inhibition 
of the cell viability of NCI/ADR-RES cells. The IC50 values 
estimated for Ir-R8, Ir2-R8 and Ir3-R8 (IC50 = 32 µM, 50 µM, 
and 13 µM, respectively) are in the same range to that of 
cisplatin (IC50 = 14 µM).24 The cytotoxicity of these 
compounds could be explained by the induction of highly 
supercoiled DNA—as observed in the AFM studies—and the 
resulting obstruction of processes requiring the access of 
proteins to the DNA (e.g., avoiding the formation of the 
replication fork, or the assembly of the transcriptional 
machinery).25 
Table 2. IC50 (µM) and Emax (%) values of Ir2, Ir2-R8 and cisplatin for NCI-H460, 
A2780 cis and MCF-7 tumoral cell lines. The evaluation have been carried out 
using MTT method. 
 NCI-H460 A2780 cis MCF-7 
Ir2 >100.0, 34.0 ± 5 35.0 ± 1, 55.0 ± 3 > 100.0, 31.0 ± 2 
Ir2-R8 15.0 ± 0.1, 91 ± 1 4.0 ± 0.2, 83 ± 1 12.0 ± 0.5, 90 ± 1 
cisplatin 6.0 ± 0.3, 68 ± 2 6.8 ± 0.2, 91 ± 1 13.0 ± 0.3, 90 ± 1 
Conclusions 
In summary, we have applied a versatile solid phase peptide 
synthesis approach for the assembly of mono, di and trinuclear 
polypyridyl Ir(III) organometallopeptides and their octaarginine 
analogs, which display high DNA binding affinity and 
sequence selectivity. The DNA binding affinity of the trinuclear 
Ir3-R8 metallopeptide is in the order of the best known organic 
DNA minor-groove binders, and, to the best of our knowledge, 
is one of the highest DNA affinity ever reported for a metal 
complex.17b,26 Moreover, these Ir(III) R8-derivatives are highly 
cytotoxic against diverse cell lines, including doxorubicin-
resistance NCI/ADR-RES and display as much activity as 
cisplatin. 
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